Understanding the role of the NMDA receptor subunit, GluN2D, in mediating NMDA receptor antagonist-induced behavioral disruptions in male and female mice.
GluN2D
NMDA
PCP
ketamine
mouse behaviour
schizophrenia
Journal
Journal of neuroscience research
ISSN: 1097-4547
Titre abrégé: J Neurosci Res
Pays: United States
ID NLM: 7600111
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
24
07
2023
received:
08
05
2023
accepted:
23
09
2023
medline:
30
1
2024
pubmed:
10
10
2023
entrez:
10
10
2023
Statut:
ppublish
Résumé
Noncompetitive NMDA receptor (NMDAR) antagonists like phencyclidine (PCP) and ketamine cause psychosis-like symptoms in healthy humans, exacerbate schizophrenia symptoms in people with the disorder, and disrupt a range of schizophrenia-relevant behaviors in rodents, including hyperlocomotion. This is negated in mice lacking the GluN2D subunit of the NMDAR, suggesting the GluN2D subunit mediates the hyperlocomotor effects of these drugs. However, the role of GluN2D in mediating other schizophrenia-relevant NMDAR antagonist-induced behavioral disturbances, and in both sexes, is unclear. This study aimed to investigate the role of the GluN2D subunit in mediating schizophrenia-relevant behaviors induced by a range of NMDA receptor antagonists. Using both male and female GluN2D knockout (KO) mice, we examined the effects of the NMDAR antagonist's PCP, the S-ketamine enantiomer (S-ket), and the ketamine metabolite R-norketamine (R-norket) on locomotor activity, anxiety-related behavior, and recognition and short-term spatial memory. GluN2D-KO mice showed a blunted locomotor response to R-norket, S-ket, and PCP, a phenotype present in both sexes. GluN2D-KO mice of both sexes showed an anxious phenotype and S-ket, R-norket, and PCP showed anxiolytic effects that were dependent on sex and genotype. S-ket disrupted spatial recognition memory in females and novel object recognition memory in both sexes, independent of genotype. This datum identifies a role for the GluN2D subunit in sex-specific effects of NMDAR antagonists and on the differential effects of the R- and S-ket enantiomers.
Substances chimiques
Esketamine
50LFG02TXD
Ketamine
690G0D6V8H
norketamine
XQY6JVF94X
Phencyclidine
J1DOI7UV76
Receptors, N-Methyl-D-Aspartate
0
Grin2d protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25257Subventions
Organisme : Monash University
Organisme : National Health and Medical Research Council
ID : APP2000893
Organisme : Society for Neurochemistry
Informations de copyright
© 2023 The Authors. Journal of Neuroscience Research published by Wiley Periodicals LLC.
Références
Brain Res Mol Brain Res. 1995 Oct;33(1):61-71
pubmed: 8774946
Pharmacol Biochem Behav. 2020 Jan;188:172839
pubmed: 31866390
J Neurosci. 2002 Mar 15;22(6):2335-42
pubmed: 11896172
Cereb Cortex. 2008 Nov;18(11):2560-73
pubmed: 18296432
Schizophr Res. 2018 Sep;199:313-318
pubmed: 29510925
Mol Psychiatry. 2021 Jun;26(6):2562-2576
pubmed: 32382134
J Psychiatr Res. 2015 Feb;61:64-72
pubmed: 25560772
Behav Brain Res. 2022 Feb 10;418:113633
pubmed: 34673124
Eur Neuropsychopharmacol. 2014 May;24(5):822-35
pubmed: 24287012
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E3007-E3016
pubmed: 29531088
Mol Psychiatry. 2021 Nov;26(11):6704-6722
pubmed: 33859356
Br J Pharmacol. 2014 Feb;171(3):799-809
pubmed: 24236947
J Neurosci. 1993 Dec;13(12):5009-28
pubmed: 8254358
Psychiatry Res. 2016 May 30;239:281-3
pubmed: 27043274
J Comp Neurol. 1994 Sep 1;347(1):150-60
pubmed: 7798379
Nat Rev Neurosci. 2013 Jun;14(6):383-400
pubmed: 23686171
J Psychopharmacol. 2020 Jan;34(1):115-124
pubmed: 31580184
Neuropharmacology. 2017 Jan;112(Pt A):188-197
pubmed: 27480795
Front Psychiatry. 2022 May 19;13:855810
pubmed: 35664490
Behav Pharmacol. 2018 Feb;29(1):13-27
pubmed: 29176430
J Neurosci Res. 2024 Jan;102(1):e25257
pubmed: 37814998
Psychopharmacology (Berl). 2009 Jun;204(2):361-73
pubmed: 19189082
Front Pharmacol. 2015 Sep 22;6:204
pubmed: 26441660
Am J Psychiatry. 1978 Sep;135(9):1081-4
pubmed: 696930
Methods Mol Biol. 2017;1677:1-80
pubmed: 28986865
Neurobiol Dis. 2019 Nov;131:104208
pubmed: 29936230
Am J Psychiatry. 2018 Dec 1;175(12):1205-1215
pubmed: 30153752
Nature. 2021 Aug;596(7871):301-305
pubmed: 34321660
Subst Use Misuse. 2014 Mar;49(4):395-404
pubmed: 24106975
PLoS One. 2010 Oct 28;5(10):e13722
pubmed: 21060893
Mol Psychiatry. 2019 Dec;24(12):1779-1786
pubmed: 31467392
J Neurosci. 2020 Sep 30;40(40):7668-7687
pubmed: 32859716
Neurosci Lett. 2016 Jan 1;610:48-53
pubmed: 26520463
Eur J Neurosci. 2001 Jul;14(1):153-60
pubmed: 11488959
Pharmacol Biochem Behav. 2019 Jun;181:53-59
pubmed: 31034852
Behav Brain Res. 2019 Oct 17;372:111984
pubmed: 31150746
Synapse. 2009 Aug;63(8):698-704
pubmed: 19391150
Pharmacol Biochem Behav. 2014 Jan;116:137-41
pubmed: 24316345
Neurobiol Dis. 2020 Feb;134:104625
pubmed: 31786371
Neurobiol Dis. 2012 Jun;46(3):722-31
pubmed: 22426399
J Neurosci. 1996 Jan;16(1):19-30
pubmed: 8613785
Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1501-1512
pubmed: 37249625
Biochem Pharmacol. 2022 Apr;198:114963
pubmed: 35182519
Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):577-582
pubmed: 32078034
Psychopharmacology (Berl). 2021 Sep;238(9):2555-2568
pubmed: 34342672
PLoS One. 2020 Jun 4;15(6):e0233895
pubmed: 32497062
Mol Pharmacol. 2016 Dec;90(6):689-702
pubmed: 27625038
Schizophr Bull. 2020 Dec 1;46(6):1482-1497
pubmed: 32506125
Pharmacol Ther. 2020 Jan;205:107426
pubmed: 31629007
Adv Pharmacol. 2016;76:351-82
pubmed: 27288082
J Pharmacol Toxicol Methods. 2020 Mar - Apr;102:106676
pubmed: 31954839
J Neural Transm (Vienna). 2019 Dec;126(12):1637-1651
pubmed: 31529297
J Neurosci. 2019 May 8;39(19):3611-3626
pubmed: 30846615
Am J Psychiatry. 2018 Jul 1;175(7):620-630
pubmed: 29656663
J Pharmacol Exp Ther. 2017 Apr;361(1):9-16
pubmed: 28115553
Eur Arch Psychiatry Clin Neurosci. 2022 Jun;272(4):693-701
pubmed: 34977960
Mol Psychiatry. 2018 Jul;23(7):1606-1613
pubmed: 29112193
NPJ Schizophr. 2017 Feb 3;3:7
pubmed: 28560253
Pharmacol Rev. 2010 Sep;62(3):405-96
pubmed: 20716669
Neuropsychopharmacology. 1995 Aug;13(1):9-19
pubmed: 8526975
Am J Psychiatry. 2022 Apr;179(4):277-287
pubmed: 35360919
Neuron. 1994 Mar;12(3):529-40
pubmed: 7512349
J Pharmacol Exp Ther. 2016 Mar;356(3):702-11
pubmed: 26675679
Mol Brain. 2013 Dec 16;6:56
pubmed: 24330819
J Vis Exp. 2017 Aug 30;(126):
pubmed: 28892027
Sci Rep. 2019 May 20;9(1):7572
pubmed: 31110197
Neuropharmacology. 2013 Nov;74:4-17
pubmed: 23376022
J Neurosci. 2020 May 13;40(20):3949-3968
pubmed: 32277042
AMA Arch Neurol Psychiatry. 1959 Mar;81(3):363-9
pubmed: 13626287
Br J Anaesth. 1985 Feb;57(2):197-203
pubmed: 3970799
Psychopharmacology (Berl). 2016 Apr;233(7):1215-25
pubmed: 26758284
Neuropharmacology. 2018 Nov;142:41-62
pubmed: 29196183
Sci Immunol. 2019 Oct 11;4(40):
pubmed: 31604844
Schizophr Res. 2015 Sep;167(1-3):98-107
pubmed: 25583246
Front Cell Neurosci. 2015 Mar 25;9:95
pubmed: 25859181
Front Behav Neurosci. 2021 Jan 14;14:620119
pubmed: 33519395
Neuropharmacology. 2021 Aug 15;194:108382
pubmed: 33144117
Eur J Pharmacol. 1997 Aug 20;333(1):99-104
pubmed: 9311667
Depress Anxiety. 2021 Nov;38(11):1120-1130
pubmed: 34293233
J Psychiatr Res. 2018 May;100:16-23
pubmed: 29475017
Neuropsychopharmacology. 2013 Dec;38(13):2613-22
pubmed: 23856634
Neurosci Biobehav Rev. 2016 Aug;67:57-78
pubmed: 26743859
Behav Brain Res. 2021 Apr 23;404:113057
pubmed: 33316322
Neurochem Res. 2019 Jan;44(1):61-77
pubmed: 29651654
Front Behav Neurosci. 2021 Jun 11;15:689193
pubmed: 34177484
Neuroimage Clin. 2014 Mar 20;4:531-9
pubmed: 24749063
Mol Psychiatry. 2015 Sep;20(9):1057-68
pubmed: 26169973
Channels (Austin). 2021 Dec;15(1):179-192
pubmed: 33509021
Biol Psychiatry. 2023 Jun 15;93(12):1118-1126
pubmed: 36841701
Transl Psychiatry. 2015 Sep 01;5:e632
pubmed: 26327690
Schizophr Res. 2017 Mar;181:107-116
pubmed: 27745755
Science. 2014 May 30;344(6187):992-7
pubmed: 24876489
Biol Psychiatry. 2016 Sep 15;80(6):424-431
pubmed: 26707087
Behav Brain Res. 2013 Nov 1;256:229-37
pubmed: 23958806
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
pubmed: 8122957
J Pharmacol Exp Ther. 2006 Jan;316(1):315-24
pubmed: 16192313
J Psychopharmacol. 2021 Feb;35(2):109-123
pubmed: 33155503
Int J Neuropsychopharmacol. 2019 Jul 1;22(7):449-452
pubmed: 31135879
Pharmacol Biochem Behav. 2011 Nov;100(1):191-8
pubmed: 21889525
Behav Brain Res. 2016 Oct 1;312:93-101
pubmed: 27312268
Lancet Psychiatry. 2019 Dec;6(12):977-979
pubmed: 31680014
Psychopharmacology (Berl). 2008 Aug;199(2):191-8
pubmed: 18446324
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jun 1;37(2):237-46
pubmed: 22361156
Neuropsychopharmacology. 2016 Aug;41(9):2206-14
pubmed: 26868058
Front Behav Neurosci. 2009 Feb 23;3:2
pubmed: 19255630
Biol Psychiatry. 2015 Jun 15;77(12):1031-40
pubmed: 25863358
Psychopharmacology (Berl). 2009 Oct;206(2):267-79
pubmed: 19597801